Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Akebia Therapeutics (AKBA) Reports Q4 Revenues Miss
March 18, 2019 4:12 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q4 revenue for the quarter came in at $59.85 million versus the consensus estimate of $73.67 million.
2018 was a transformational year for Akebia, said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have... More
